Pharmacologic effects in brain caused by systemic administration of neuropeptides are prevented by poor transport of the peptide through the brain vascular endothelium, which comprises the blood-brain barrier in vivo. In the present study, successful application of a chimeric peptide approach to enhance drug delivery through the bloodbrain barrier for the purpose of achieving a central nervous system pharmacologic effect is described. The chimeric peptide was formed by linkage of a potent vasoactive intestinal peptide (VIP) analogue, which had been monobiotinylated, to a drug transport vector. The vector consisted of a covalent conijugate of avidin and the OX26 monoclonal antibody to the transferrin receptor. Owing to the high concentration of transferrin receptors on brain capillary endothelia, OX26 targets brain and undergoes receptor-mediated transcytosis through the bloodbrain barrier. Systemic infusion of low doses (12 pug/kg) of the VIP chimeric peptide in rats resulted in an in vivo central nervous system pharmacologic effect: a 65% increase in cerebral blood flow. Biotinylated VIP analogue without the brain transport vector was ineffective.Morphological, biochemical, and functional evidence indicates that vasoactive intestinal polypeptide (VIP) is a potent cerebrovascular vasodilator (1-6). Although VIP causes vasodilation in vitro (7, 8) and when applied locally to intracranial blood vessels (9), no consistent cerebrovascular effects could be demonstrated after systemic application of the peptide (10-12). This exemplifies the prohibitive role played by the blood-brain barrier (BBB) in limiting peptide transport to brain and subsequent neuropharmacologic effects. The use of chimeric peptides offers an approach to enhanced brain delivery of such peptides: drugs that normally do not cross the BBB may be coupled to brain drug transport vectors (13).Brain drug transport vectors include proteins such as cationized albumin (14) or the OX26 monoclonal antibody (15), which undergo absorptive-or receptor-mediated transcytosis through the BBB, respectively. OX26 is a murine monoclonal antibody directed against the rat transferrmn receptor (16). The transferrin receptor is highly expressed on brain capillary endothelium (16, 17) and allows for receptormediated transcytosis of circulating transferrin (18) or the OX26 monoclonal antibody (15,19) through the BBB.Coupling of drugs to brain transport vectors such as OX26 is facilitated by use of the avidin-biotin system (20), and cbupling of avidin to the transport vectors enables their potential application to delivery of biotinylated peptides or antisense oligonucleotides (21,22). However, an essential requirement for a biotinylated ligand of an avidin transport vector conjugate is monobiotinylation. Higher degrees of biotinylation inevitably cause aggregation by avidin, which has four binding sites for biotin (23). Therefore, in the present studies, a VIP analogue (VIPa) suitable for monobiotinylation was developed. To demonstrate an in vivo pharmacologic eff...